Published in Women's Health Weekly, August 15th, 2002
The task force also recommended against the use of these drugs by women at low or average risk for breast cancer.
The task force, an independent panel of experts that is sponsored by the Agency for Healthcare Research and Quality (AHRQ), reviewed three randomized controlled trials that studied the use of the drug tamoxifen and one study on the off-label use of the drug raloxifene to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly